Elsevier

Neuroscience Letters

Volume 90, Issue 3, 1 August 1988, Pages 349-353
Neuroscience Letters

Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse; evidence for subcellular sequestration as basis for cellular resistance to the toxicant

https://doi.org/10.1016/0304-3940(88)90214-5Get rights and content

Abstract

Administration to mice of the neurotoxicant MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) decreased striatal dopamine and, to a lesser extent, hippocampal noradrenaline levels when measured 2 weeks after the last dose of MPTP. Reserpine and tetrabenazine, inhibitors of the catecholamine vesicular transporter, potentiated the catecholamine depletions produced by MPTP in the hippocampus and striatum, respectively. These results are compatible with our hypothesis that sequestration of the toxic MPTP metabolite MPP+ (1-methyl-4-phenylpyridinium) in the catecholamine storage vesicle retards the catecholaminergic toxicity of MPTP.

References (11)

There are more references available in the full text version of this article.

Cited by (33)

  • Current Status, Gaps, and Weaknesses of the Mechanism of Selective Dopaminergic Toxicity of MPTP/MPP<sup>+</sup>

    2017, Advances in Molecular Toxicology
    Citation Excerpt :

    The physiological significance of these differences is not clearly understood. As mentioned above, numerous previous studies suggest that the active accumulation of MPP+ in dopaminergic synaptic vesicles through VMAT2 protects the dopaminergic cells from MPP+ toxicity [100,102–105]. This proposal is based on the argument that the synaptic accumulation limits the availability of cytosolic MPP+ for mitochondrial entry and complex I inhibition which are vital for the proposed mechanism of the neurotoxicity of MPP+.

  • Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons

    2003, Brain Research
    Citation Excerpt :

    Surprisingly, we observed that TBZ treatment (30 mg/kg, s.c.) performed 90 min before injecting 6-OHDA or MPP+, protected from both toxins. Reinhard Jr. et al. [31] have observed that a treatment with TBZ, 30 min before MPTP i.p. injection, potentiates the neurotoxicity undergone by mice. The discrepancy between the results of Naudin et al. [28], Reinhard Jr. et al. [31] and ours, may be explained by the time course of the TBZ side effects, such as hypothermia, and that a delay of 30 min between administration of TBZ and the toxin is insufficient to obtain a marked inhibition of the VMAT2.

View all citing articles on Scopus
View full text